Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SJP002 in Healthy Korean Males
NCT02924155Phase 1Completed
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rebamipide in dry eye syndrome (DED) (2 arms), sponsored by Samjin Pharmaceutical Co., Ltd. Primary endpoint: Incidence of Treatment Emergent Adverse Event. Started Sep 2016; status: completed.
02
Drugs
rebamipide
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02924155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924155.